-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*It is only for medical professionals to read and refer to the domestic trastuzumab, which can reduce the "waste of residual fluid", has come out! Domestic trastuzumab helps standardize the clinical diagnosis and treatment of breast cancer through the flexible delivery method of "small specifications and multiple combinations", bringing more benefits to patients with HER2-positive breast cancer
.
Breast cancer is the malignant tumor with the highest incidence in women.
Trastuzumab-based anti-HER2 targeted therapy has reduced the risk of recurrence in nearly half of patients, making it possible for advanced breast cancer to cease to be a "terminally ill" dream.
The clinical pattern of breast cancer patients has been changed
.
However, before 2019, only one imported trastuzumab was approved for listing in China, and it was expensive and large in specifications, and required "surplus liquid management"
.
From a medical professional point of view, trastuzumab, which requires "surplus fluid management", is not the most ideal therapeutic drug, and it is easy to cause safety concerns for patients
.
In this regard, we specially invited Gao Wei, the head nurse of Shandong University Qilu Hospital, to focus on the problem of "surplus fluid management" in the entire management process of breast cancer anti-HER2 treatment
.
Solving the problem of "residual fluid management" is crucial to realizing the standardization of the entire diagnosis and treatment of anti-HER2 breast cancer.
The head nurse Gao Wei introduced that under the high-load nursing workload, the nursing team needs to continuously optimize daily management work to provide better patients.
The treatment and nursing care of the patients includes the problem of "remaining liquid management" of the liquid medicine
.
According to the quality control standards, each nurse generally manages the medicines of more than a dozen patients at the same time.
The workload is extremely heavy.
It takes up too much time and energy that the nurses should spend on the physical and mental care of the patients
.
"Especially in the new normal crown epidemic, force majeure factors such as hospital emergency closure caused by repeated outbreaks cause the patient to the hospital in accordance with the agreed dates can not use the possible waste of trastuzumab, pharmaceuticals, also delayed treatment of patients
.
As a Medical workers, we are very unwilling to see such a situation, so we have been thinking about how to simplify the'remaining fluid management'.
We desperately need a trastuzumab that does not require the'remaining fluid management'
.
" Gao Wei Said the head nurse
.
What is gratifying is that with the development of biopharmaceutical technology in China, small-strength trastuzumab, which is more suitable for Chinese patients, has been clinically approved
.
At present, domestic trastuzumab has been included in medical insurance
.
"Small-size, multiple-combination" "ready-to-use" model avoids the risk of preservative use and guarantees patient safety.
According to the head nurse Gao Wei, domestic trastuzumab mainly contains two sizes of 150mg and 60mg.
"Small size, The flexible dosing method of "multi-combination" better meets the treatment needs of patients with different weights, and greatly reduces the "waste of residual fluid"
.
At the same time, the domestic trastuzumab “ready to use” concept not only guarantees high-quality treatment effects, but also removes patients’ doubts about preservatives, and further dispels patients’ concerns about adverse reactions.
A better medication experience for patients is the best of both worlds
.
"At present, in the actual clinical application process, we have received positive feedback from patients
.
I also look forward to not only breast cancer patients but also patients with other cancer types benefiting from the strong domestic drug research and development in the near future
.
"Head Nurse Gao Wei said
.
Expert profile Gao Wei, head nurse, deputy chief nurse, Qilu Hospital of Shandong University Deputy leader of the group, member of the Case Management Committee of Shandong Nursing Society, member of the Day Surgery Development and Promotion Branch of Shandong Research Hospital Association, published 1 SCI paper and more than ten core journal papers as the first author, and won the Shandong Provincial Nursing Innovation Reform One third prize for the activity, presided over one school-level education and teaching reform of Shandong University in 2020, served as a part-time teacher of Shandong University School of Nursing, and for many years undertook clinical internship teaching work for students of Shandong University School of Nursing *This information is only for medicine and scientific research For reference, it is not recommended to use this product in any way that is inconsistent with the prescription information approved in your country.
.
Breast cancer is the malignant tumor with the highest incidence in women.
Trastuzumab-based anti-HER2 targeted therapy has reduced the risk of recurrence in nearly half of patients, making it possible for advanced breast cancer to cease to be a "terminally ill" dream.
The clinical pattern of breast cancer patients has been changed
.
However, before 2019, only one imported trastuzumab was approved for listing in China, and it was expensive and large in specifications, and required "surplus liquid management"
.
From a medical professional point of view, trastuzumab, which requires "surplus fluid management", is not the most ideal therapeutic drug, and it is easy to cause safety concerns for patients
.
In this regard, we specially invited Gao Wei, the head nurse of Shandong University Qilu Hospital, to focus on the problem of "surplus fluid management" in the entire management process of breast cancer anti-HER2 treatment
.
Solving the problem of "residual fluid management" is crucial to realizing the standardization of the entire diagnosis and treatment of anti-HER2 breast cancer.
The head nurse Gao Wei introduced that under the high-load nursing workload, the nursing team needs to continuously optimize daily management work to provide better patients.
The treatment and nursing care of the patients includes the problem of "remaining liquid management" of the liquid medicine
.
According to the quality control standards, each nurse generally manages the medicines of more than a dozen patients at the same time.
The workload is extremely heavy.
It takes up too much time and energy that the nurses should spend on the physical and mental care of the patients
.
"Especially in the new normal crown epidemic, force majeure factors such as hospital emergency closure caused by repeated outbreaks cause the patient to the hospital in accordance with the agreed dates can not use the possible waste of trastuzumab, pharmaceuticals, also delayed treatment of patients
.
As a Medical workers, we are very unwilling to see such a situation, so we have been thinking about how to simplify the'remaining fluid management'.
We desperately need a trastuzumab that does not require the'remaining fluid management'
.
" Gao Wei Said the head nurse
.
What is gratifying is that with the development of biopharmaceutical technology in China, small-strength trastuzumab, which is more suitable for Chinese patients, has been clinically approved
.
At present, domestic trastuzumab has been included in medical insurance
.
"Small-size, multiple-combination" "ready-to-use" model avoids the risk of preservative use and guarantees patient safety.
According to the head nurse Gao Wei, domestic trastuzumab mainly contains two sizes of 150mg and 60mg.
"Small size, The flexible dosing method of "multi-combination" better meets the treatment needs of patients with different weights, and greatly reduces the "waste of residual fluid"
.
At the same time, the domestic trastuzumab “ready to use” concept not only guarantees high-quality treatment effects, but also removes patients’ doubts about preservatives, and further dispels patients’ concerns about adverse reactions.
A better medication experience for patients is the best of both worlds
.
"At present, in the actual clinical application process, we have received positive feedback from patients
.
I also look forward to not only breast cancer patients but also patients with other cancer types benefiting from the strong domestic drug research and development in the near future
.
"Head Nurse Gao Wei said
.
Expert profile Gao Wei, head nurse, deputy chief nurse, Qilu Hospital of Shandong University Deputy leader of the group, member of the Case Management Committee of Shandong Nursing Society, member of the Day Surgery Development and Promotion Branch of Shandong Research Hospital Association, published 1 SCI paper and more than ten core journal papers as the first author, and won the Shandong Provincial Nursing Innovation Reform One third prize for the activity, presided over one school-level education and teaching reform of Shandong University in 2020, served as a part-time teacher of Shandong University School of Nursing, and for many years undertook clinical internship teaching work for students of Shandong University School of Nursing *This information is only for medicine and scientific research For reference, it is not recommended to use this product in any way that is inconsistent with the prescription information approved in your country.
